| Followers | 144 |
| Posts | 27987 |
| Boards Moderated | 5 |
| Alias Born | 02/07/2004 |
Friday, July 11, 2008 10:13:03 AM
ALERT (SYMBOL: TEVA)
Teva intends to sue over generic FDA filing for Copaxone
By MarketWatch
7/11/2008 10:08:46 AM
Dubi
Recent TEVA News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2026 10:36:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2026 10:28:47 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2026 10:22:25 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/03/2026 10:46:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/03/2026 10:34:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/03/2026 10:25:46 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/03/2026 10:13:29 PM
- Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug • GlobeNewswire Inc. • 03/03/2026 10:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/02/2026 09:01:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/26/2026 09:11:04 PM
- Teva to Present at the Upcoming Investor Conferences in March • GlobeNewswire Inc. • 02/24/2026 09:30:00 PM
- Medincell: U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults • Business Wire • 02/20/2026 08:37:00 PM
- Medincell : La FDA américaine accepte le dossier de demande de mise sur le marché déposé par Teva pour l’Olanzapine LAI • Business Wire • 02/20/2026 08:37:00 PM
- U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults • GlobeNewswire Inc. • 02/20/2026 07:43:11 PM
- Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease • GlobeNewswire Inc. • 02/17/2026 11:00:00 AM
- Teva Canada Announces Approval of Expanded Indication of [Pr]AJOVY® (fremanezumab solution for subcutaneous injection), the First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine • PR Newswire (Canada) • 02/04/2026 01:05:00 PM
- Teva Canada annonce l'approbation de l'indication élargie de [Pr]AJOVY[MD] (frémanézumab, solution pour injection sous cutanée), le premier traitement préventif anti-CGRP indiqué pour la migraine épisodique pédiatrique • PR Newswire (Canada) • 02/04/2026 01:05:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/03/2026 01:58:40 PM
- Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential • GlobeNewswire Inc. • 01/28/2026 12:00:00 PM
- Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’ • GlobeNewswire Inc. • 01/27/2026 01:00:00 PM
- AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine • GlobeNewswire Inc. • 01/14/2026 10:02:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2026 11:00:59 AM
- Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation • GlobeNewswire Inc. • 01/11/2026 11:00:00 PM
- Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo • GlobeNewswire Inc. • 01/11/2026 10:15:00 PM
- Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo • GlobeNewswire Inc. • 01/11/2026 10:00:00 PM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT) • BLOZF • Mar 16, 2026 8:37 AM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
